Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 7707 results

  1. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

    Awaiting development [GID-TA11556] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044

    Awaiting development [GID-TA11558] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Accuro handheld ultrasound device for locating intervertebral space for administration of spinal anaesthesia

      Status ...

    Medical technologies guidance
    Topic selection

  4. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

      Status ...

    Diagnostics guidance
    Topic selection

  5. Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure

    Awaiting development [GID-IPG10404] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  6. In-situ Normothermic Regional Perfusion system for DCD donors

    Awaiting development [GID-IPG10405] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  7. Insertion of neo-chordae into the beating heart for mitral regurgitation

    In development [GID-IPG10216] Expected publication date: TBC

    Interventional procedures guidance
    In development

  8. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]

    Awaiting development [GID-TA10791] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015

    Awaiting development [GID-TA11551] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Zoll ThermoGuard XP for Intravascular Temperature Management

      Status ...

    Medical technologies guidance
    Topic selection

  13. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  14. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development [GID-TA11092] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development [GID-TA11094] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development